Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide

Leukemia & Lymphoma ◽

10.1080/10428190902718800 ◽

2009 ◽

Vol 50 (4) ◽

pp. 653-655

Author(s):

Frank G. Basile

Keyword(s):

Elderly Patient ◽

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Cytogenetic Remission ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Complete Remission Following Chemotherapy with Low-dose Cytosine Arabinoside and Macrophage Colony-stimulating Factor/Granulocyte Colony-stimulating Factor in a Patient with Relapsed Acute Myeloid Leukemia after Stem Cell Transplantation

Internal Medicine ◽

10.2169/internalmedicine.51.7933 ◽

2012 ◽

Vol 51 (20) ◽

pp. 2937-2941 ◽

Author(s):

Kohei Okada ◽

Asumi Higashiyama ◽

Mutsumi Takahata ◽

Masahiro Onozawa ◽

Kaoru Kahata ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Macrophage Colony Stimulating Factor ◽

Macrophage Colony ◽

Stimulating Factor ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Hypoplastic acute myeloid leukemia in an elderly patient. A long‐term partial remission with low‐dose prednisone and G‐CSF

Clinical Case Reports ◽

10.1002/ccr3.2204 ◽

2019 ◽

Vol 7 (7) ◽

pp. 1285-1290

Author(s):

Anwarul Islam

Keyword(s):

Elderly Patient ◽

Acute Myeloid Leukemia ◽

Partial Remission ◽

Myeloid Leukemia ◽

Low Dose ◽

Dose Prednisone ◽

Download Full-text

Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults

European Journal Of Haematology ◽

10.1111/j.0902-4441.2006.t01-1-ejh2570.x ◽

2006 ◽

Vol 77 (4) ◽

pp. 345-348 ◽

Author(s):

Kazunari Yamada ◽

Masako Mizusawa ◽

Akane Harima ◽

Koichi Kajiwara ◽

Tamae Hamaki ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Cord Blood Transplantation ◽

Unrelated Donor ◽

Blood Transplantation ◽

Low Dose Cytarabine ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21)

Leukemia Research ◽

10.1016/j.leukres.2010.11.003 ◽

2011 ◽

Vol 35 (5) ◽

pp. 604-607 ◽

Author(s):

Ying Wang ◽

Weiyang Li ◽

Suning Chen ◽

Huiying Qiu ◽

Aining Sun ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Salvage Chemotherapy ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Stimulating Factor ◽

Low Dose Cytarabine ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations

OncoTargets and Therapy ◽

10.2147/ott.s161919 ◽

2018 ◽

Vol Volume 11 ◽

pp. 6863-6870 ◽

Author(s):

Limin Li ◽

Xiaoqian Zhang ◽

Hongjuan Yu ◽

Mingwen Zhang ◽

Mengyuan Xu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Poor Risk ◽

Hypomethylating Agent ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Review for "Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial"

10.1002/hon.2755/v1/review1 ◽

2020 ◽

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Low Dose ◽

Download Full-text

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Case Medical Research ◽

10.31525/ct1-nct04113616 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Low Dose ◽

Safety And Efficacy ◽

Multicenter Phase ◽

Phase 1B ◽

Low Dose Cytarabine ◽

Download Full-text

Faculty Opinions recommendation of A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119427.575617 ◽

2008 ◽

Author(s):

Arati Rao

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Low Dose ◽

Randomized Study ◽

Line Therapy ◽

Low Dose Cytarabine ◽

Download Full-text

Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation ◽

10.1038/s41409-021-01434-3 ◽

2021 ◽

Author(s):

Iman Abou Dalle ◽

Ali Bazarbachi

Keyword(s):

Acute Myeloid Leukemia ◽

Cell Transplantation ◽

Myeloid Leukemia ◽

Actinomycin D ◽

Hematopoietic Cell Transplantation ◽

Hematopoietic Cell ◽

Allogeneic Hematopoietic Cell Transplantation ◽

Relapsed Acute Myeloid Leukemia ◽

Download Full-text

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Annals of Hematology ◽

10.1007/s00277-021-04545-5 ◽

2021 ◽

Author(s):

Michael Heuser ◽

B. Douglas Smith ◽

Walter Fiedler ◽

Mikkael A. Sekeres ◽

Pau Montesinos ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Clinical Benefit ◽

Myeloid Leukemia ◽

Low Dose ◽

De Novo ◽

Secondary Acute Myeloid Leukemia ◽

Term Analysis ◽

Low Dose Cytarabine ◽

Download Full-text